#recurrence risk

1 story

#ascon 2026 #bntx #business #cancer vaccine #finance #melanoma #merck #moderna #nvax #oncology congress #phase 2b

Moderna Stock Rises 6% on Cancer Vaccine Data
Moderna stock climbs 6% after melanoma vaccine data shows 49% lower recurrence risk.
Yahoo Finance · 2m